National Academies Press: OpenBook
« Previous: 4. Comparison of Disease Burdens
Suggested Citation:"5. Predictions of Vaccine Development." Institute of Medicine. 1986. New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press. doi: 10.17226/920.
×

5
Predictions on Vaccine Development

THE NEED FOR PREDICTIONS

Predictions about specific vaccines and the processes used to develop them are an integral part of the selection scheme outlined in Chapter 3. These predictions are required to calculate the health benefits expected from each new vaccine and the associated costs. The characteristics of a vaccine (e.g., live attenuated virus versus subunit) may affect its efficacy, and the complexity of the development process determines the costs associated with producing health benefits and the time at which they would be achieved.

This chapter describes the types of predictions in the analysis. Predictions were developed separately for each vaccine/disease combination, based on the available literature and various other sources. The final predictions were made after extensive discussions within the committee and consultations with many individuals in academic institutions, government, and industry.

SELECTION OF CANDIDATES

The committee defined candidates for accelerated development as those vaccines for which development was foreseeable within the next decade. The criterion for inclusion was whether a reasonable consensus could be identified on the nature of potential vaccine components (protective antigens). (The selection process is described further in Appendix A.)

The diseases and vaccine candidates chosen for the ranking process are shown in Tables 5.1 and 5.2 and described in detail in Appendixes D-1 through D-19. Some marginal candidates were excluded (because of

Much of the material in this chapter is from New Vaccine Development: Establishing Priorities, Volume I (Institute of Medicine, 1985). However, some sections, like the one on predictions of vaccine efficacy, have been changed to reflect the special requirements of health care delivery in developing countries.

Suggested Citation:"5. Predictions of Vaccine Development." Institute of Medicine. 1986. New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press. doi: 10.17226/920.
×

TABLE 5.1 Predictions Table—Primary

Pathogen (Target Population)

Type of Vaccine

Cost of Development ($ millions)

Probability of Successful Development

Dengue virus (Infants and children in endemic areas; travelers to endemic areas)

Attenuated live vector virus containing gene for broadly cross-reacting protective antigen

25

0.75

Escherichia coli (enterotoxigenic) (Infants<6 months)

A combination of purified colonization factor antigens and possibly other antigens

25

0.50

Genetically engineered attenuated strains

25–50

0.70

Hemophilus influenzae type b (Infants)

Conjugated polysaccharide

15

0.90

Hepatitis A virus (Susceptibles of all ages; routine for preschool children)

Attenuated live virus

15

0.95

Polypeptide recombinant vaccine produced in yeast

25

0.95

Hepatitis B virus (Areas with high perinatal infection: all infants at birth (if possible). Other areas: all infants, simultaneous with other vaccinations, at earliest possible age)

Polypeptide produced by recombinant DNA technology

5

0.99

Japanese encephalitis virus (Children in epidemic and endemic areas; foreign visitors to epidemic regions)

Inactivated virus produced in cell culture

50

0.50

Mycobacterium leprae (Immunoprophylactic: all children in endemic areas. Immunotherapeutic: all recently infected individuals)

Armadillo-derived M. leprae

25

0.50

Neisseria meningitidis (Infants, 3 to 6 months)

Conjugated capsular polysaccharides. Groups A,C,Y, and W135

30

0.50 (dependent upon success in developing conjugation procedures with other vaccines)

Parainfluenza viruses (Infants)

Trivalent, subunit vaccine (which must contain fusion proteins)

25

0.80

Plasmodium spp. (All infants at risk, military personnel, travelers)

Plasmodium falciparum, synthetic or recombinant sporozoite antigen preparation

25

0.50

Multivalent synthetic or recombinant sporozoite antigen preparation (P. falciparum, P. vivax, P. ovale, P. malariae)

35

0.50

Suggested Citation:"5. Predictions of Vaccine Development." Institute of Medicine. 1986. New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press. doi: 10.17226/920.
×

Time to Licensure (years)

Time to Adoption (years)

Efficacy

Number of doses

Cost per dose (dollars)

10

2

0.85

1

12

10

2

0.75

(against strains in vaccine)

Approx. 3

5–10

10

2

0.80

(against strains in vaccine)

1–2

1–2

3

5

0.90

2 (with DTP)

5–10

4

5

(as part of combination)

0.90

1

15

5

5

0.90

3

20

1

2

(dependent on price)

0.90

3

30

6–8

2–3

0.80

2

(boosters required with all current; none gives life-long immunity)

10–20

10

5

0.75

1

25

4–6

5

(in moderate to high risk areas)

0.80

2

10

5

5

0.80

(against severe disease in young children)

2+boosters

15

5–8

2

0.80

(assuming immunity is long-lasting)

3

10–15

8–10

2

0.80

(assuming immunity is long-lasting)

3

10–15

Suggested Citation:"5. Predictions of Vaccine Development." Institute of Medicine. 1986. New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press. doi: 10.17226/920.
×

Pathogen (Target Population)

Type of Vaccine

Cost of Development ($ millions)

Probability of Successful Development

Rabies virus

(Individuals at high risk, plus post-exposure prophylaxis)

Vero cell

5

0.90

(Same)

Glycoprotein produced by rDNA technology in mammalian cells

3–5

0.85

(Birth cohort in areas of high risk)

Attenuated live vector virus containing gene for protective glycoprotein antigen

10–20

0.50

Respiratory syncytial virus

(Infants at earliest possible age)

Polypeptides produced by recombinant DNA technology

25

0.80

Attenuated live virus

25

0.80

Rotavirus

(Infants at earliest possible age, preferably with oral polio vaccine)

Attenuated high passage bovine rotavirus

10

0.90

Attenuated low passage bovine rotavirus

30

0.80

Rhesus monkey rotavirus

30

0.80

Salmonella typhi

(Children; young adults at risk; travelers from developed countries to endemic areas)

Attenuated ga1E mutant S. typhi strain TY21a

2

0.90

Aromatic amino acid dependent strains of S. typhi

2

0.50

Shigella spp.

(Infants at birth or earliest possible age; elderly for epidemic strains)

Probably plasmid mediated outer membrane protein invasion determinant (small number of promising options need investigation to determine best approach)

25–50

0.70

for polyvalent vaccine

(0.85 for targeted S. dysenteriae and S. flexneri strains)

Streptococcus A

(Children,<3 to 4 years)

Synthetic M protein segment (excluding portions cross-reacting with human tissue)

50

0.80

Streptococcus pneumoniae

(Infants)

Conjugated polysaccharides, polyvalent

30

0.80

Vibrio cholera

(Children, especially <2 years)

Genetically defined live mutant V. cholerae (A−B+ or A−B− with respect to toxin subunit synthesis

25

0.75

Inactivated antigens

10

0.65

Yellow fever virus

(Young children)

Attenuated live virus produced in cell culture

15

0.95

Suggested Citation:"5. Predictions of Vaccine Development." Institute of Medicine. 1986. New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press. doi: 10.17226/920.
×

Time to Licensure (years)

Time to Adoption (years)

Efficacy

Number of doses

Cost per dose (dollars)

3

2–5

(dependent on price)

0.99

3–5

10

3

2–5

(dependent on price)

0.95

3–5

10

3

2

0.95

1

1

5

2

0.80

(against severe disease in young children)

2+booster

15

5

2

0.80

(against severe disease in young children)

1–2

15

2

2

0.80

(against severe disease in young children)

1

10

5

2

0.90

(against severe disease in young children)

1

10

5

2

0.90

(against severe disease in young children)

1

10

1

2

(endemic areas)

0.80

2–3

2

5–8

 

0.80–0.90

2–3

2

approx. 10

2

0.80–0.90

(for a multivalent vaccine)

1–2

2

6–8

2–5

0.80

(depends on adjuvant or carrier development)

2

5

5

2

0.80

1–2

20

5–7

2

0.90

1–2

2

3–5

2

0.65

2–3

2

2–4

2

(endemic areas)

0.90

1

5

Suggested Citation:"5. Predictions of Vaccine Development." Institute of Medicine. 1986. New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press. doi: 10.17226/920.
×

TABLE 5.2 Predictions Table—Secondary

Pathogen (Target Population)

Type of Vaccine

Clinical Trial Difficulty

Dengue virus

(Infants and children in endemic areas; travelers to endemic areas)

Attenuated live vector virus containing gene for broadly cross-reacting protective antigen

Phase I trials must be in adults, in nonendemic areas. Some apprehension over possible enhancement effects for dengue and with new approach

Escherichia coli

(enterotoxigenic)

(Infants < 6 months)

A combination of purified colonization factor antigens and possibly other antigens

Moderate. High attack rate in children and travelers makes evaluation possible in relatively small population. But may need to evaluate protection against certain serotypes or CFA types

Genetically engineered attenuated strains

Needs careful monitoring for reversion to virulence

Hemophilus influenzae type b

(Infants)

Conjugated polysaccharide

Need to be carried out in very young children

Hepatitis A virus

(Susceptibles of all ages; routine for preschool children)

Attenuated live virus

Large number of subjects needed. Initial trials in adults may give false concepts of immunogenicity and reactogenicity for children

Polypeptide recombinant vaccine produced in yeast

Large number of subjects needed

Hepatitis B virus

(Areas with high perinatal infection: all infants at birth (if possible). Other areas: all infants, simultaneous with other vaccinations, at earliest possible age)

Polypeptide produced by recombinant DNA technology

Relatively simple

Japanese encephalitis virus

(Children in epidemic and endemic areas; foreign visitors to epidemic regions)

Inactivated virus produced in cell culture

Difficult. Low clinical attack rate requires very large number of subjects.

Mycobacterium leprae

(Immunoprophylactic: all children in endemic areas. Immuno therapeutic: all recently infected individuals)

Armadillo-derived M. leprae

Low incidence and long incubation period requires many subjects and long time for trials

Neisseria meningitidis

(Infants, 3 to 6 months)

Conjugated capsular polysaccharides, Groups A,C,Y, and W135

Difficult because epidemic disease is unpredictable

Parainfluenza viruses

(Infants)

Trivalent, subunit vaccine

(which must contain fusion proteins)

 

Plasmodium spp.

(All infants at risk, military personnel, travelers)

Plasmodium falciparum, synthetic or recombinant sporozoite antigen preparation

Mosquito challenge to volunteers

Multivalent synthetic or recombinant sporozoite antigen preparation

(P. falciparum, P. vivax, P. ovale, P. malariae)

Mosquito challenge to volunteers

Suggested Citation:"5. Predictions of Vaccine Development." Institute of Medicine. 1986. New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press. doi: 10.17226/920.
×

Route of Administration

Adverse Reactions

Delivery Requirements

Incorporation into EPI

Intradermal

Low grade fever, soreness, muscle aches

Cold chain required; possible freeze-drying in future

Yes

Oral

None

Adjuvant use may reduce number of doses

Yes

Oral

Possibly mild diarrhea in 20%

Cold chain for lyophilized bacteria; adjuvant may be needed

Yes

Intramuscular

5% local

Refrigeration

If in a polyvalent vaccine

Parenteral, subcutaneous, or intramuscular

Minimal

Refrigeration of lyophilized preparation

As a combination with IPV and other antigens

Subcutaneous or intramuscular

Minimal

Refrigeration

Might be combined with other nonliving vaccines

Intramuscular or subcutaneous

Negligible

Refrigeration

Could be incorporated at present; efficacy much improved if delivery possible at birth, i.e., with modified EPI schedules

Subcutaneous

Some possibility of life-threatening effects associated with current vaccines: allergic encephalomyelitis; acute viral encephalitis

Nothing unusual

Yes

 

Feasible

Intramuscular

Minor local

Refrigeration

Feasible

Subcutaneous

None

Nothing unusual

 

Subcutaneous or intramuscular

No data—unknown

Adjuvant required, probably alum

Probably

Subcutaneous or intramuscular

No data—unknown

Nothing unusual

Probably

Suggested Citation:"5. Predictions of Vaccine Development." Institute of Medicine. 1986. New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press. doi: 10.17226/920.
×

Pathogen

(Target Population)

Type of Vaccine

Clinical Trial Difficulty

Rabies virus

(Individuals at high risk, plus post-exposure prophylaxis)

Vero cell

Little; depends on antibody response

(Same)

Glycoprotein produced by rDNA technology in mammalian cells

Fatal natural disease and current availability of effective vaccine require rigorous proof of likely efficacy prior to field trials

(Birth cohort in areas of high risk)

Attenuated live vector virus containing gene for protective glycoprotein antigen

Some possible apprehension over new approach

Respiratory syncytial virus

(Infants)

Polypeptides produced by recombinant DNA technology

Difficult. Needed very early in life; need rapid response. Vaccines won’t take in persons with antibodies

Attenuated live virus

 

Rotavirus

(Infants, 0–6 months)

Attenuated high passage bovine rotavirus

Relatively easy. Pathogen present everywhere in world. Can do trial in children<1 year

Attenuated low passage bovine rotavirus

Rhesus monkey rotavirus

Salmonella typhi

(Children; young adults at risk; travelers from developed countries to endemic areas)

Attenuated ga1E mutant S. typhi strain TY21a

Trials largely completed; further work needed to optimize vaccine

Aromatic amino acid dependent strains of S. typhi

Shigella spp.

(Infants at birth or earliest possible age; elderly for epidemic strains)

Probably plasmid mediated outer membrane protein invasion determinant (small number of promising options need investigation to determine best approach)

Moderate to difficult

Streptococcus A

(Children,<3 to 4 years)

Synthetic M protein segment

(excluding portions cross-reacting with human tissue)

Moderate to very difficult

Streptococcus pneumoniae

(Infants)

Conjugated polysaccharides, polyvalent

Requires high degree of patient and physician cooperation. Multitude of bacterial types creates problems of accurately determining vaccine efficacy

Vibrio cholera

(Children, especially <2 years)

Genetically defined live mutant V. cholerae (A−B+ or A−B−) with respect to toxin subunit synthesis

Difficult. Need large populations in hyperendemic areas. Screening possible in volunteers

Inactivated antigens

Difficult. Same problems as live

Yellow fever virus

(Young children)

Attenuated live virus produced in cell culture

Ethical problems in field testing an improved vaccine when an effective one already exists

Suggested Citation:"5. Predictions of Vaccine Development." Institute of Medicine. 1986. New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press. doi: 10.17226/920.
×

Route of Administration

Adverse Reactions

Delivery Requirements

Incorporation into EPI

Intramuscular or subcutaneous

Slight/none

Refrigeration

Probably not warranted. Duration of immunity not certain and post-exposure prophylaxis strategy preferred

Same as at present

(with alum adjuvant)

Fewer reactions than current vaccine

Nothing unusual

Same

Probably intradermal

Unknown

Probably nothing unusual

Probably, depending on duration of immunity

Subcutaneous

None

Nothing unusual

Feasible

Intranasal

None

Nothing unusual

Feasible

Oral

Minimal or none

Refrigeration and must be administered with food or milk

Yes

Oral (an alternative to enteric-coated capsules, i.e., a liquid vaccine formula, may be needed for infants and young children)

None seen

Refrigeration and moisture control for enteric-coated capsules

Feasible (if new vaccine formulation is developed)

None

 

 

Oral

None

Probably lyophilization; possibly enteric-coated capsules

Feasible

Intramuscular

 

 

Readily incorporated

Parenteral

Local soreness, low grade fever

Refrigeration (4 C)

Feasible, dependent on cost

Oral

Present prototypes cause mild diarrhea in 20%

Cold chain for lyophilized bacteria

Feasible

Oral

None expected

Lyophilized probably will withstand moderate ambient temperatures

Probably promptly in endemic areas

Subcutaneous

Minimal

Refrigeration

Feasible

Suggested Citation:"5. Predictions of Vaccine Development." Institute of Medicine. 1986. New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press. doi: 10.17226/920.
×

staff resource constraints), and the prospects for their development are discussed briefly in the supplement to this volume (see Appendix I). This supplement also includes information on pathogens that cause major global disease problems but that were considered unsuitable for accelerated vaccine development at this time.

VACCINE CANDIDATES AND TARGET POPULATIONS

One or more vaccine candidates for accelerated development have been identified for each disease. Vaccine descriptions usually are based on current research in specific areas. in some cases, however, the number of vaccine possibilities led the committee to base predictions on a combination of research findings and general knowledge about probable requirements for licensure.

To identify an appropriate vaccine target population, the committee considered the age distribution of the disease consequences (particularly of those conditions considered most desirable to avoid); the relative risk of illness in various geographic population groups; and accessibility to the health care system. For reasons described in the next chapter, the committee assumed that most of the vaccine candidates would be delivered through the World Health Organization Expanded Program on Immunization (WHO-EPI). The effects of this assumption on determinations of vaccine efficacy are outlined below.

PREDICTIONS ON VACCINE DEVELOPMENT

Predictions on vaccine development are an attempt to foresee events from 1985 until the time at which vaccine licensure might occur. Predictions are based solely on technical feasibility and not on judgments about the desirability of particular courses of action; no distinction has been made between public and private sector developmental resources.

Probability of Successful Development

The likelihood of bringing a specific vaccine to licensure within the time allotted, and with the predicted efficacy and other characteristics, is described as the probability of successful development. This probability is based on the state of current research, the complexity of the problem (e.g., the number of known serologic types), and characteristics of the natural immune response. The committee assumed that vaccine candidates would have to comply with safety and efficacy standards similar to those required by U.S. licensing regulations and the WHO.

Suggested Citation:"5. Predictions of Vaccine Development." Institute of Medicine. 1986. New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press. doi: 10.17226/920.
×

Cost of Development

The estimate for the cost of development includes all future costs needed to bring the vaccine to licensure, irrespective of the funding source. Factors considered in estimating this amount were the current state of vaccine development, the complexity of the problem (e.g., difficulties encountered in culturing the pathogen), the availability of animal models, the number of alternatives to be tested in human clinical trials, and possible difficulties in conducting clinical trials or in establishing efficacy and safety in the target population.

Time to Licensure

The time to licensure is defined as the shortest time in which a vaccine could be licensed, if all developmental stages are completed without major delays. Factors considered in determining this time were similar to those for estimating the cost of development.

The committee also considered interrelationships among the probability of success, the cost of development, and the time to licensure; for example, the extent to which extra funding could significantly reduce the time to licensure for a particular vaccine.

PREDICTIONS ON VACCINE CHARACTERISTICS

The committee based its predictions on the characteristics of individual vaccines primarily on known characteristics of existing vaccines of similar type, for example, live attenuated virus, polysaccharide, or subunit vaccine. These predictions also incorporate assumptions about likely licensure requirements.

Efficacy

The prediction of a vaccine’s efficacy represents a population-based measure of protection rather than a measure of antibody production in an individual and is given by

Factors considered in estimating the efficacy were the type of pathogen and number of serotypes involved in the disease, the nature of the vaccine candidate, and the extent of immunity from natural infection.

Vaccine efficacy predictions also incorporate the assumption that vaccines will be administered at ages compatible with delivery through EPI (see Appendixes D-1 through D-19 for specific details). unfortunately, the EPI delivery schedule may not be ideal for some

Suggested Citation:"5. Predictions of Vaccine Development." Institute of Medicine. 1986. New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press. doi: 10.17226/920.
×

candidates. Efficacy would be affected if recipients were unable to respond fully or to maintain immunity for a sufficient length of time.

Adverse Reactions

Adverse side effects of a vaccine, especially those likely to occur at very low frequency, are extremely difficult to predict but can seriously affect vaccine acceptance. Predictions about side effects are based on the nature of the new vaccine and its purity, and on observations of similar existing vaccines. To facilitate calculations, predictions concerning the incidence of adverse reactions are best expressed “per dose” rather than “per vaccinee.”

In this analysis, anticipated adverse reactions were judged, for the vaccines considered, to be negligible for the purposes of calculating potential vaccine benefits (see Chapter 7). For new contenders the likely reactions and their frequency should be evaluated to determine if an adjustment of the potential health benefits, which accounts for adverse reactions, is warranted.

Production Technology, Delivery Requirements, and Cost per Dose

The technical difficulty of producing a vaccine and the delivery (storage) requirements affect vaccine cost. The committee based its predictions in these areas on the nature of each vaccine candidate and on requirements for existing similar vaccines. Production technology and delivery requirements also affect the cost per dose, which, in turn, may affect vaccine acceptance.

Number of Doses and Route of Administration

The number of doses necessary to achieve a vaccine’s predicted protective efficacy and the route of administration also may affect the ease of integrating the vaccine into existing immunization programs. Predictions of these characteristics are based largely on the nature (including the probable antigenicity) of each vaccine candidate.

CONCLUSIONS

The predictions in Tables 5.1 and 5.2 resulted from extensive deliberations by the full committee on estimates made by a subgroup, with suggested revisions by many outside consultants. The predictions were designed to reflect relative differences in vaccine candidates’ prospects for development; they are not intended to be precise descriptions of future events. Predicting vaccine development is complicated by many factors, including the rapid pace of new advances in biotechnology. Some candidates excluded from the current analysis

Suggested Citation:"5. Predictions of Vaccine Development." Institute of Medicine. 1986. New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press. doi: 10.17226/920.
×

(but discussed in the supplement to this volume) may soon need to be reassessed.

Although the outcome of scientific investigations cannot be predicted, the committee believes that the estimates and probabilities in Tables 5.1 and 5.2 are reasonable because they are based more on developmental than basic research investigations. The factors considered in arriving at each prediction have been stated in as much detail as possible, in the belief that regular reappraisal of these factors is essential. The flexibility of the model described in this report makes it easy to substitute alternative or updated predictions as they become available.

REFERENCE

Institute of Medicine. 1985. New Vaccine Development: Establishing Priorities, Volume I. Diseases of Importance in the United States. Washington, D.C.: National Academy Press.

Suggested Citation:"5. Predictions of Vaccine Development." Institute of Medicine. 1986. New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press. doi: 10.17226/920.
×
Page 63
Suggested Citation:"5. Predictions of Vaccine Development." Institute of Medicine. 1986. New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press. doi: 10.17226/920.
×
Page 64
Suggested Citation:"5. Predictions of Vaccine Development." Institute of Medicine. 1986. New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press. doi: 10.17226/920.
×
Page 65
Suggested Citation:"5. Predictions of Vaccine Development." Institute of Medicine. 1986. New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press. doi: 10.17226/920.
×
Page 66
Suggested Citation:"5. Predictions of Vaccine Development." Institute of Medicine. 1986. New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press. doi: 10.17226/920.
×
Page 67
Suggested Citation:"5. Predictions of Vaccine Development." Institute of Medicine. 1986. New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press. doi: 10.17226/920.
×
Page 68
Suggested Citation:"5. Predictions of Vaccine Development." Institute of Medicine. 1986. New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press. doi: 10.17226/920.
×
Page 69
Suggested Citation:"5. Predictions of Vaccine Development." Institute of Medicine. 1986. New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press. doi: 10.17226/920.
×
Page 70
Suggested Citation:"5. Predictions of Vaccine Development." Institute of Medicine. 1986. New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press. doi: 10.17226/920.
×
Page 71
Suggested Citation:"5. Predictions of Vaccine Development." Institute of Medicine. 1986. New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press. doi: 10.17226/920.
×
Page 72
Suggested Citation:"5. Predictions of Vaccine Development." Institute of Medicine. 1986. New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press. doi: 10.17226/920.
×
Page 73
Suggested Citation:"5. Predictions of Vaccine Development." Institute of Medicine. 1986. New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press. doi: 10.17226/920.
×
Page 74
Suggested Citation:"5. Predictions of Vaccine Development." Institute of Medicine. 1986. New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press. doi: 10.17226/920.
×
Page 75
Next: 6. Assessing the Likely Utilization of New Vaccines »
New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries Get This Book
×
Buy Paperback | $65.00
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

Common diseases cost the developing world an enormous amount in terms of human life, health, and productivity, as well as lost economic potential. New and effective vaccines could not only improve the quality of life for millions of residents in developing countries, they could also contribute substantially to further economic development. Using data from the World Health Organization and other international agencies, this book analyzes disease burdens, pathogen descriptions, geographic distribution of diseases, probable vaccine target populations, alternative control measures and treatments, and future prospects for vaccine development. New Vaccine Development provides valuable insight into immunological and international health policy priorities.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!